Clinical Trials
Please contact your Abramson Cancer Center Oncologist about enrollment into a trial. If you do not have an Abramson Cancer Center Oncologist, please contact our Pancreas Nurse Navigator Patricia Gambino at 215-615-0537 or Patricia.Gambino@uphs.upenn.edu to make an appointment with one of our Oncologists to discuss clinical trials.
| Adjuvant | ||||
|---|---|---|---|---|
| Trial # | Trial | Type of therapy | Description | PI/Contact |
| UPCC 04218 | Immunotherapy | Adjuvant | Pilot study of mature dendritic cell vaccination against mutated KRAS in patients with resectable pancreatic cancer (KRAS dendritic cell vaccine with cyclophosphamide lymphodepletion) | Adham Bear/Mark O'Hara |
| EA2192 (APOLLO) | Olaparib | Adjuvant | Randomized, double blind study of olaparib vs placebo following adjuvant platinum based chemotherapy in patients with respectable pancreatic adenocarcinoma and a pathogenic BRCA1, BRCA2 or PALB2 mutation |
Mary Oladjei/Kim Reiss |
|
UPCC 24922 (Elicio) |
Immunotherapy | Adjuvant | First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for subjects with Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS viral oncogene homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and other solid tumors (P: ELI-002 7P - a therapeutic vaccine |
Mark O'Hara/Christina Haas/Christine Amartey |
| Neoadjuvant | ||||
|---|---|---|---|---|
| Trial # | Trial | Type of therapy | Description | PI/Contact |
|
UPCC 24223 (Columbia U) |
Immunotherapy, radiation therapy, surgical resection | Neoadjuvant | A Phase 2, open-label, multicenter, randomized study evaluating neoadjuvant therapy targeting the adenosine immunosuppressive pathway in combination with immune checkpoint blockade and radiation therapy in patients with advanced pancreatic ductal adenocarcinoma who are candidates for surgical resection. (Drugs: Zimberelimab (AB122; anti-PD-1), Quemliclustat (AB680 anti-CD73), Etrumadenant (AB298; A2a/A2b inhibitor) | Mark O'Hara/Alyssa Donze/Asal Kareem |
| Localized, Resectable | ||||
|---|---|---|---|---|
| Trial # | Trial | Type of therapy | Description | PI/Contact |
|
Localized, Unresectable |
||||
|---|---|---|---|---|
| Trial # | Trial | Type of therapy | Description | PI/Contact |
| UPCC 32213 | Radiation & nab®-Paclitaxel | Locally advanced | A phase I dual dose escalation study of radiation and nab-paclitaxel in patients with unresectable and borderline resectable pancreatic cancer | Taylor Siegal/Edgar Ben-Josef |
| Metastatic trials — First Line (Initial treatment for newly metastatic diagnosis) | ||||
|---|---|---|---|---|
| Trial # | Trial | Type of therapy | Description | PI/Contact |
|
UPCC 07220 (ARCUS) |
AB680 (CD73 inhibitor) | 1st line metastatic | Phase I study to evaluate the safety and tolerability of AB680 combination therapy in participants with gastrointestinal malignancies (gem/abraxane, AB680 (CD73 inhibitor that decreases adenosine) | Mark O'Hara/Natalia Izgur/Carla Wright |
|
UPCC 07224 (RevMed) Subprotocol A [limited slots] |
RMC-6236 (RAS-MULTI(ON) inhibitor) |
1st line metastatic | Subprotocol A: RMC-6236 with 5-fluorouracil-based regimens in mPDAC | Mark O’Hara/Jennifer Kandle, Natallia Izgur, Asal Kareem |
|
UPCC 07224 (RevMed) Subprotocol C [limited slots] |
RMC-6236 (RAS-MULTI(ON) inhibitor) |
1st line metastatic | Subprotocol C: RMC-6236 and Gemcitabine with Nab-paclitaxel in mPDAC | Mark O’Hara/Jennifer Kandle, Natallia Izgur, Asal Kareem |
|
UPCC 23222 (Verastem) |
Gemcitabine, nab-paclitaxel, defactinib, avutometinib |
1st line metastatic | A Phase lb/2a Study of Gemcitabine and Nab-paclitaxel in Combination with Avutometinib (vS-6766) and Defactinib in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas | Mark O'Hara/Natallia Izgur, Carla Wright |
| Metastatic Trials — Second Line | ||||
|---|---|---|---|---|
| Trial # | Trial | Type of therapy | Description | PI/Contact |
| UPCC 03821 | Modified human CAR T cells | 2nd line - Metastatic Pancreatic Cancer | Phase I study of human CAR modified T cells (huCART-meso) administered in combination with VCN-01 (hyaluronidase-secreting oncolytic adenovirus) in PDAC and ovarian cancers. ECOG 0 patients preferred | Kim Shea/Mark O'Hara |
|
UPCC 07224 (RevMed) Subprotocol B [limited slots] |
RMC-6236 (RAS-MULTI(ON) inhibitor) |
2nd line metastatic (no more than 1 line of prior systemic anticancer therapy in the metastatic setting) |
Subprotocol B: RMC-6236 and Cetuximab in mPDAC | Mark O’Hara/Jennifer Kandle, Natallia Izgur, Asal Kareem |
| UPCC 18223 | Gemcitabine, GP-2250 (metabolic inhibitor) | 2nd line metastatic | A Phase 1 trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GP-2250 in combination with gemcitabine in subjects with advanced unresectable or metastatic pancreatic adenocarcinoma who have progressed on prior treatment with 5-fluorouacil-based chemotherapy | Jennifer Kandle/Mark O'Hara |
| Metastatic Maintenance | ||||
|---|---|---|---|---|
| Trial # | Trial | Type of therapy | Description | PI/Contact |
|
SIV S2001 |
PARP inhibitor | 1st line - Maintenance Metastatic | A randomized Phase II clinical trial of Olaparib + Pembrolizumab vs. Olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with Germline BRCA1 or BRCA2 mutations | Kim Reiss |
| Biomarker Trials | ||||
|---|---|---|---|---|
| Trial # | Trial | Type of therapy | Description | PI/Contact |
|
UPCC 16224 |
Pancreatic tissue acquisition | No therapy | Protocol to permit the acquisition of samples of tumor and normal tissue for biological endpoints in pancreatic cancer | Kim Reiss/Ben Stanger/Sean O'Connor |
| UPCC 02215 | Circulating tumor material | No therapy | Protocol to permit the acquisition of circulating tumor material in pancreatic diseases and control subjects | Peter O'Dwyer |
| UPCC 20222 | Blood sample | No therapy | Protocol to permit collection of circulating biomarkers in pancreatic cancer | Asal Kareem/Mark O'Hara |
Please contact your Abramson Cancer Center Oncologist about enrollment into a trial. If you do not have an Abramson Cancer Center Oncologist, please contact our Pancreas Nurse Navigator Patricia Gambino at 215-615-0537 or patricia.gambino@uphs.upenn.edu to make an appointment with one to discuss clinical trials.
Please note that openings for clinical trials are highly variable. Consequently, at any given time there may not be open slots for the trials shown here. Conversely, slots may be available for clinical trials that have not yet been listed on this page. To determine whether a clinical trial may be appropriate for you, please contact your Abramson Cancer Center Oncologist at 1-800-789-7366.